Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
UPDATE: Arcturus Therapeutics (ARCT) PT Raised to $30 at Goldman Sachs (CORRECTION)
November 9, 2021 6:51 AM EST(Updated - November 9, 2021 6:52 AM EST)
Goldman Sachs analyst Madhu Kumar raised the price target on Arcturus Therapeutics (NASDAQ: ARCT) to $30.00 (from $28.00) while maintaining a Sell rating.
... MoreArcturus Therapeutics (ARCT) Misses Q3 EPS by 46c
November 8, 2021 4:28 PM ESTArcturus Therapeutics (NASDAQ: ARCT) reported Q3 EPS of ($2.05), $0.46 worse than the analyst estimate of ($1.59).
For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.
... More